[Duration of effect and dose-response relationship of a new beta-sympatholytic agent in comparison with pindolol in patients with coronary heart disease].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005449:Fluorenes / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D005449:Fluorenes; D011412:Propanolamines; D010869:Pindolol
Wirkungsdauer und Dosiswirkungsbeziehungen einer neuen beta-sympatholytischen Substanz im Vergleich mit Pindolol bei Patienten mit koronarer Herzkrankheit.